Cost-effective non-additive GWAS across 2329 diseases in 500,349 individuals
Abstract Drug candidates supported by genetic evidence are more likely to succeed in clinical trials, with genome-wide association studies (GWAS) providing a key source of such evidence. Standard GWAS approaches assume additive effects of alleles on the phenotype, but non-additive models have also s...
Сохранить в:
| Главные авторы: | , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Nature Portfolio
2025-12-01
|
| Серии: | Nature Communications |
| Online-ссылка: | https://doi.org/10.1038/s41467-025-67277-4 |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|